1. Introduction {#sec1-cancers-12-00956}
===============

Ovarian cancer (OC) is the most severe gynecologic malignancy with stable incidence and mortality. The most frequent OC types (85--95%) are epithelial tumors, which are high-grade (HG) serous in 70% of cases \[[@B1-cancers-12-00956],[@B2-cancers-12-00956]\]. Because of the nonspecific symptoms and a lack of presymptomatic screening modalities, most women are diagnosed with an advanced disease, having a dismal 25% 5-year survival rate \[[@B3-cancers-12-00956]\].

The overall OC lifetime risk oscillates around 2% in the general female population in developed countries. Central and Eastern Europe, including the Czech Republic, represented a region with the highest OC incidence (11.9 ASRW per 100,000 females) and mortality (6.0 ASRW per 100,000 females) worldwide in 2018 (<http://gco.iarc.fr>). In the Czech Republic alone, annual OC incidence and mortality in 2018 reached 9.5 and 6.7 ASRW per 100,000 females, respectively.

Genetic predisposition for OC is unusually high and is reported in up to 25% of cases \[[@B4-cancers-12-00956],[@B5-cancers-12-00956],[@B6-cancers-12-00956]\]. The most frequent germline mutations affect the *BRCA1* and *BRCA2* genes, conferring 24% and 8.4% OC lifetime risks, respectively \[[@B7-cancers-12-00956]\]. The *BRCA1* and *BRCA2* mutation carriers frequently but not exclusively develop HG serous OC \[[@B8-cancers-12-00956]\]. Carriers of mutations in these major OC predisposition genes have also very high risk of breast cancer (BC) development. A high OC risk has also been associated with germline mutations in *RAD51C, RAD51D,* Lynch syndrome genes, and *STK11*; a moderate OC risk with *BRIP1* \[[@B9-cancers-12-00956],[@B10-cancers-12-00956],[@B11-cancers-12-00956],[@B12-cancers-12-00956],[@B13-cancers-12-00956]\]. Risks associated with germline mutations in genes with anticipated BC and/or OC predisposition (incl. *ATM, BARD1, CDH1, CHEK2, NBN, PALB2*, *PTEN,* and *TP53*) and in other candidate genes remain to be determined \[[@B14-cancers-12-00956],[@B15-cancers-12-00956],[@B16-cancers-12-00956],[@B17-cancers-12-00956]\]. The identification of presymptomatic women at high risk who can benefit from risk-reducing salpingo-oophorectomy (RRSO) is of critical importance, as demonstrated by the reduced OC mortality in *BRCA1* and *BRCA2* mutation carriers undergoing preventive surgery \[[@B18-cancers-12-00956]\].

In this report, we aim to establish an association of germline mutations with OC in the Czech patients belonging to the Slavic population that has not been systematically analyzed for OC predisposition. Seven Czech genetic laboratories participated in the analysis of 1333 Czech OC patients by the identical procedure using CZECANCA panel (CZEch CAncer paNel for Clinical Application) targeting 219 genes \[[@B19-cancers-12-00956]\]. Prevalence of variants in genes affected in OC patients was assessed in 2278 population-matched controls. This analysis enabled us to comprehensively determine mutations frequency and clinicopathological characteristics of OC in carriers of mutations in genes with known OC predisposition but also to analyze contribution of population-specific variants in other candidate genes to OC predisposition.

2. Results {#sec2-cancers-12-00956}
==========

2.1. Description of Study Population {#sec2dot1-cancers-12-00956}
------------------------------------

Altogether, samples obtained from 1333 OC patients diagnosed at seven centers were analyzed by the identical panel NGS using the CZECANCA panel targeting 219 cancer-predisposition and candidate genes and were evaluated centrally by the identical bioinformatics pipeline. From 1333 analyzed OC patients, 1045 (78.4%) women were diagnosed with OC only and 288 (21.6%) women with double primary tumors, including BC (210 patients; 15.8%) or other tumors (78 patients; 5.9%). The median age at OC diagnosis was 53.7 years (range 15--86 years). Almost half (47.6%) of the patients had a negative family cancer history. From 1120 OC patients with known histology, 728 (65.0%) women developed serous adenocarcinoma with prevailing HG tumors. Sixty percent of cases represented patients with advanced disease (stages III--IV). The clinicopathological characteristics are provided in [Table S1](#app1-cancers-12-00956){ref-type="app"}.

2.2. Mutations in 18 Known/Anticipated Hereditary BC/OC Genes {#sec2dot2-cancers-12-00956}
-------------------------------------------------------------

We primarily focused on mutations in 18 BC/OC genes listed in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2020; 4 December 2019). We identified 441 mutations in 427/1333 (32.0%) OC patients and 58/2278 (2.5%) mutation carriers among population-matched controls (PMC) in 18 known/anticipated BC/OC genes ([Figure 1](#cancers-12-00956-f001){ref-type="fig"}, [Table 1](#cancers-12-00956-t001){ref-type="table"}, and [Table S2](#app1-cancers-12-00956){ref-type="app"}). Thirteen multiple mutation carriers ([Figure 1](#cancers-12-00956-f001){ref-type="fig"}) identified among patients only (characterized in [Table S3](#app1-cancers-12-00956){ref-type="app"}) were excluded from the subsequent analyses.

Carriers of germline mutations in 10 genes (including Lynch syndrome genes analyzed as a group together) had significantly increased OC risk ([Table 1](#cancers-12-00956-t001){ref-type="table"} in bold). We found the prevailing *BRCA1* or *BRCA2* germline alterations in 323/1320 (24.5%) patients and in 12/2278 (0.5%) PMC. Further, 65/1320 (4.9%) OC patients carried a mutation in 8 other genes significantly associated with OC risk in our study (including 2 carriers of mutations in *STK11*, an established high-risk OC gene that did not reach significant association in our study due to low frequency of mutation carriers in patients; [Figure 1](#cancers-12-00956-f001){ref-type="fig"}). We found only 19/2278 (0.8%) carriers of mutations in these 8 genes in PMC.

The copy number variation (CNV) analysis in 18 OC/BC genes revealed 37 large genomic rearrangements in 37/1333 (2.8%) patients. They affected seven genes (23×*BRCA1*, 4×*BRIP1*, 4×*CHEK2*, 2×*MLH1*, 2×*STK11*, 1×*PALB2*, and 1×*CDH1*) and accounted for 8.4% (37/441) of all pathogenic mutations in these genes. Except 1 whole gene duplication of *MSH6* (classified as VUS), we found no CNV in analyzed controls in these 18 genes.

2.3. Clinical and Histopathological Characteristics of Mutation Carriers {#sec2dot3-cancers-12-00956}
------------------------------------------------------------------------

Subsequently, we described the clinicopathological characteristics of the mutation carriers in 10 genes associated with OC risk ([Figure 2](#cancers-12-00956-f002){ref-type="fig"} and [Table S4](#app1-cancers-12-00956){ref-type="app"}). Multiple mutation carriers ([Table S3](#app1-cancers-12-00956){ref-type="app"}) were excluded from this analysis.

### 2.3.1. Age at OC Diagnosis {#sec2dot3dot1-cancers-12-00956}

The highest mutation frequency was found in patients diagnosed with OC at 40--49 and 50--59 years (37.4% and 40.7%, respectively) and the lowest in patients diagnosed before the age of 30 (8.3%; [Figure 2](#cancers-12-00956-f002){ref-type="fig"}A). Interestingly, the mutation frequency in the group of the oldest patients (≥70 years) was twice higher than in the youngest (\<30 years) patients' subgroup (*p* = 0.013 for difference). This difference was primarily caused by *BRCA1*/*BRCA2* mutations (3.6% vs. 18.1% in patients \<30 vs. ≥70 years), as the frequency of *non-BRCA* genes mutations was similar (4.8% vs. 4.3%). The median age at diagnosis was significantly different in *BRCA1* (51.0 years; range 23--78) and *BRCA2* (58.4 years; range 27--78) mutation carriers (*p* = 8.5×10^−10^), respectively. The median age at diagnosis in other genes with at least 10 identified mutation carriers increased gradually from *RAD51C* (52.2 years; range 25--69) to *NBN* (54.5 years; range 18--76), *RAD51D* (56.0 years; range 36--69), and *BRIP1* (58.0 years; range 30--71). We observed a younger median age at diagnosis in carriers of mutations in Lynch syndrome genes 46.0 years (range 35--73).

### 2.3.2. Personal and Family Cancer History {#sec2dot3dot2-cancers-12-00956}

The highest proportion of mutations (109/203; 53.7%) was detected in double primary OC and BC patients, while in patients diagnosed with OC only and double primary OC and non-BC cancer, it reached 256/1038 (24.7%) and 21/79 (26.6%), respectively ([Figure 2](#cancers-12-00956-f002){ref-type="fig"}B). The frequency of mutations in patients from hereditary OC families (HOC) was 49.1% (57/116; [Figure 2](#cancers-12-00956-f002){ref-type="fig"}C). Decreasing proportion of mutation carriers in other family cancer history categories (41.0% in HBOC and 29.4% in multiple cancer) was dominantly caused by decreasing *BRCA1* mutation prevalence. Nevertheless, in 587 OC patients without a positive family cancer history, we still identified 120 (20.4%) carriers of pathogenic mutations.

### 2.3.3. Stage and Histology {#sec2dot3dot3-cancers-12-00956}

Almost 60% of patients were diagnosed at FIGO stage III or IV ([Figure 2](#cancers-12-00956-f002){ref-type="fig"}D). In contrast, 6/8 informative Lynch syndrome gene mutation carriers were diagnosed with stage I tumors.

The mutation rate stratified OC into two histological clusters. The high mutation rate subgroup included 879 patients with HG/unspecified serous, borderline, and endometrioid tumors with 303 (34.5%) carriers, while the low mutation rate subgroup included 232 patients with low-grade (LG) serous, mucinous, clear cell, and other tumors with 28 (12.1%) carriers. *BRCA1/2* mutations in HG serous carcinomas were more than twice as frequent (146/472; 30.9%) as in LG serous ones (11/84; 13.1%). Interestingly, the distribution of *BRIP1/RAD51C*/*RAD51D* mutations among histological types was similar to that of *BRCA1/2*. The lowest proportion of mutations (7/90; 7.8%) was found in rare histological cancer types (herein denominated as "Other").

2.4. Mutations in Additional 201 Analyzed Genes {#sec2dot4-cancers-12-00956}
-----------------------------------------------

Finally, we reviewed the presence of germline variants in additional 201 genes targeted by the CZECANCA panel \[[@B19-cancers-12-00956]\]. This analysis revealed 230 mutations in 89 genes in 208 (15.6%) patients ([Table S5](#app1-cancers-12-00956){ref-type="app"}). Of these, 149 (11.2%) patients carried mutations in "additional" genes exclusively while 59 (4.4%) patients carried a mutation in "additional" genes alongside a mutation in one of the 10 OC risk genes. Mutations in these "additional" genes were rare and their prevalence was significantly higher in patients over controls in only four genes ([Table 2](#cancers-12-00956-t002){ref-type="table"}). However, only mutations in *PPM1D* were significantly associated with OC risk (*p* = 0.003) following Bonferroni correction and exclusion of carriers of mutations in OC predisposition genes. All *PPM1D* mutations were mosaic with MAF = 14%--60% and MAF = 17%--19% in patients and controls, respectively. It should be noted that blood for genetic testing was sampled after the application of chemotherapy in all *PPM1D* positive patients (in average at 38 months after treatment; ranged 4 months--7.1 years). Seven out of 15 *PPM1D* mutation carriers harbored an additional mutation in another DNA repair gene (3×*BRCA2*, 1×*PALB2*, 1×*EXO1*, and 1×*PMS1*). MAF of *PPM1D* mutations correlated neither with age at OC diagnosis nor with the time from the last chemotherapy ([Table S6](#app1-cancers-12-00956){ref-type="app"}). Mutations in *PPM1D* and *SHPRH* were significantly associated only with age \> 60 years (*p* = 0.001), whereas frequency of *NAT1* mutations in particular categories was similar ([Table S7](#app1-cancers-12-00956){ref-type="app"}). Uncorrected p values were marginally significant also for germline variants in *MMP8* and *FANCG* in OC patients when carriers of mutations in 10 BC/OC predisposition genes significantly associating with OC risk in our study were excluded ([Table 2](#cancers-12-00956-t002){ref-type="table"}).

3. Discussion {#sec3-cancers-12-00956}
=============

The analysis of 1333 Czech OC patients and 2278 population-matched controls provides the most comprehensive view of the genetic architecture of OC predisposition in the Slavic population. From 18 OC/BC predisposition genes listed in current NCCN breast/ovarian familial cancer guidelines, mutations in 10 genes were significantly associated with OC risk in our population being present in 399/1333 (29.9%) OC patients and 31/2278 (1.4%) PMC ([Figure 1](#cancers-12-00956-f001){ref-type="fig"}). Mutations in eight remaining genes were extremely rare (*CDH1, PTEN, STK11,* and *TP53*) or absent (*CDKN2A* and *NF1*) or did not significantly differ in frequency among cases and controls (*ATM, PALB2,* and *CHEK2*). Mutations in *BRCA1/2, RAD51C/D,* and Lynch syndrome genes were associated with a high OC risk, while mutations in *BRIP1* were associated with a moderate OC risk in our study ([Table 1](#cancers-12-00956-t001){ref-type="table"}), in concordance with previous reports \[[@B9-cancers-12-00956],[@B10-cancers-12-00956],[@B20-cancers-12-00956],[@B21-cancers-12-00956]\]. The *BRCA1* and *BRCA2* mutations, present in 84.0% of all mutation carriers, were by far the most frequent alterations found in 17.9% and 7.4% of our patients, respectively. Mutations in other eight genes leaded by *RAD51C/RAD51D/BRIP1* affected additional 5.0% of patients, as shown also by others recently \[[@B5-cancers-12-00956],[@B6-cancers-12-00956],[@B22-cancers-12-00956]\]. Germline mutations in Lynch syndrome genes together associated with high OC risk. Mutations in *MLH1* prevailed similarly as in Lynch syndrome patients diagnosed with colorectal cancer \[[@B23-cancers-12-00956]\].

In contrast to previous studies, our results suggest increased OC risk in carriers of *NBN* and *BARD1* mutations \[[@B12-cancers-12-00956],[@B24-cancers-12-00956]\]. We did not find significant increase of OC risk for carriers of mutations in *ATM* and *PALB2*, as noticed previously \[[@B12-cancers-12-00956],[@B24-cancers-12-00956],[@B25-cancers-12-00956]\]. However, further analyses considering very large population-matched studies or studies considering families of mutation carriers can better disclose moderate risk associations, as shown for *PALB2* mutations recently \[[@B26-cancers-12-00956]\].

Overrepresentation of mutations in the *CHEK2* gene in OC patients in this study was marginally nonsignificant in contrast to our previous report where we identified moderately increased OC risk for *CHEK2* mutation carriers \[[@B27-cancers-12-00956]\]. However, last four *CHEK2* coding exons were not targeted in our gene panel omitting possible deleterious *CHEK2* alterations identified in our previous study in which last four coding exons were analyzed separately in both cases and controls. Mutations in *NF1* were absent and were extremely rare in *CDH1* and *PTEN*, just like *STK11* mutations found in a patient with nonepithelial OC, a characteristic Peutz--Jeghers syndrome manifestation \[[@B9-cancers-12-00956]\]. Altogether, the high overall frequency of mutations in OC predisposition genes in our study is in agreement with some previous studies \[[@B4-cancers-12-00956],[@B5-cancers-12-00956],[@B6-cancers-12-00956],[@B28-cancers-12-00956]\] and may contribute to a high OC incidence in our population.

Multigene testing revealed 13 carriers of multiple pathogenic mutations (1.0% of patients). Similar frequency of individuals with this multilocus inherited neoplasia alleles syndrome (MINAS) \[[@B29-cancers-12-00956]\] was shown also in previous analyses of OC patients \[[@B30-cancers-12-00956],[@B31-cancers-12-00956]\].

We analyzed available phenotype characteristics in 1320 OC patients with one pathogenic mutation at the most in 10 genes associated with OC risk in our study ([Figure 2](#cancers-12-00956-f002){ref-type="fig"}). While the highest prevalence of *BRCA1/2* mutation carriers was in patients diagnosed with double primary OC and BC, mutations in *RAD51C/RAD51D/BRIP1* prevailed in patients diagnosed with OC only ([Figure 2](#cancers-12-00956-f002){ref-type="fig"}B); nevertheless, their distribution among histological subtypes was similar to that in *BRCA1/2* mutation carriers ([Figure 2](#cancers-12-00956-f002){ref-type="fig"}E). In contrast to Castera et al. who found mutations in *RAD51C/RAD51D/BRIP1* dominantly in French OC patients with a positive family OC history \[[@B32-cancers-12-00956]\], we identified mutations in these genes in 1/116 (0.9%) and 22/587 (3.7%) carriers in HOC patients and in patients with a negative family cancer history, respectively. Further, we have noticed a surprisingly high frequency of OC-predisposing mutations in older patients. Their prevalence in patients ≥ 60 years was 23.6%, whereas Harter et al. found in this age group 18.9% mutation carriers even though frequency of mutation carriers in patients \<60 years in both studies was comparable (32.6% and 33.2%, respectively) \[[@B28-cancers-12-00956]\]. *BRCA1* mutations dominated in patients \<60 years over *BRCA2* mutations, while in patients ≥ 60 years, their frequencies were comparable. Moreover, we revealed 29 *BRCA1/2* mutation carriers (13.9% of patients) in 208 OC patients diagnosed at ≥60 years with no family cancer history, while Morgan and colleagues detected only two (4.3%) *BRCA1/2* mutations in 46 sporadic OC patients ≥ 60 years \[[@B33-cancers-12-00956]\]. Even in the oldest subgroup of our OC patients diagnosed at ≥70 years, the frequency of *BRCA1/2* mutation carriers exceeded 18%, while in other studies, *BRCA1/2* mutations' frequency in this age category was below 10% \[[@B34-cancers-12-00956],[@B35-cancers-12-00956]\]. This high frequency of *BRCA1/2* mutations in our patients ≥70 years contrasted with a low frequency in women diagnosed at \<30 years (18.1% vs. 3.6%; *p* = 0.003; [Figure 2](#cancers-12-00956-f002){ref-type="fig"}A). The difference was even more apparent in "sporadic" OC cases (with no family cancer history), where *BRCA1/2* mutations were found in 6 out of 45 (13.3%) women ≥70 years but in none of 52 cases diagnosed at \<30 years. It should be emphasized that although rare histological OC types were more frequent in the subgroup of 52 patients diagnosed with sporadic OC at \<30 years, 32 (65.3%) of 49 informative cases developed invasive epithelial OC.

Mutations in OC predisposition genes significantly prevailed in subgroups with high-grade/ nonspecified serous, borderline, and endometrioid tumors over subgroup with low-grade serous, mucinous, clear cell, or other rare histologic types ([Figure 2](#cancers-12-00956-f002){ref-type="fig"}E). Surprisingly, the overall mutation frequency in patients with borderline tumors was comparable with that of in HG serous OC (32.2% and 36.7%, respectively; [Figure 2](#cancers-12-00956-f002){ref-type="fig"}E). Thus, we compared mutation frequency in patients with no family cancer history diagnosed with these histological tumor types, and we found that although the mutation frequency in sporadic borderline tumors was half in comparison to sporadic HG serous ([Figure 3](#cancers-12-00956-f003){ref-type="fig"}), it still largely exceeded 10% in both hereditary and sporadic cases, justifying the genetic testing of borderline tumors. The large proportion of borderline tumors with positive family cancer history in our study suggested that this OC subtypes belong to a possible manifestation of a cancer predisposition. However, our observation needs to be confirmed in other populations as current reports about borderline tumors in *BRCA1/2* mutation carriers are limited.

The multigene panel enabled us to identify other candidate genes associating with increased OC risk. We noticed many rare truncating variants episodically affecting various genes and clustering into *PPM1D*, *NAT1*, and *SHPRH* in OC patients. The *PPM1D* gene, coding for WIP1 phosphatase, was the only candidate associated with OC risk following multiple testing correction. Similarly to the previous studies describing its mosaic variants in OC patients \[[@B36-cancers-12-00956],[@B37-cancers-12-00956],[@B38-cancers-12-00956]\], we also found mosaic gain-of-function mutations resulting in increased WIP1 phosphatase activity \[[@B38-cancers-12-00956]\]. All *PPM1D* mutations in our patients were identified in postchemotherapy treatment blood samples suggesting their somatic origin \[[@B39-cancers-12-00956]\]. Germline mutations in *NAT1* have not been analyzed for OC predisposition so far. However, several polymorphisms in *NAT1* (coding for arylamine N-acetyltransferase 1 engaged in carcinogen metabolism and detoxification) were shown to modify the risk of various cancers \[[@B40-cancers-12-00956],[@B41-cancers-12-00956]\]. The *SHPRH* gene codes for E3 ubiquitin-protein ligase targeting PCNA upon DNA damage \[[@B42-cancers-12-00956]\]. Contribution of *SHPRH* germline variants to OC risk remains elusive. Overall, low mutation frequencies found in gene candidates in our study precluded its precise OC risk estimations and will require large, multiethnic, case-control studies, segregation analyses in affected families, and functional analyses. Alongside variants clustering to a few candidate genes, we identified rare mutations in a gene family coding for Fanconi anemia (FA) proteins involved in the repair of DNA interstrand crosslinks \[[@B43-cancers-12-00956]\]. Several FA genes belong to established OC predisposition genes, including *BRCA1* (*FANCS*), *BRCA2 (FANCD1*), *RAD51C (FANCO)*, *PALB2 (FANCN)*, and *BRIP1 (FANCJ).* Except these, we found rare mutations in other FA genes (*FANCG*, *FANCD2*, and *FANCA*) in 11 (0.83%) of 1333 OC patients compared to 5 in 2278 PMC (0.2%), with cumulative OR = 3.78 (95% CI 1.21--13.91; *p* = 0.02). Interestingly, these rare mutations were detected almost exclusively in patients without mutations in other OC predisposition genes.

The strengths of this study include an identical NGS analysis and bioinformatics pipeline in all patients, a careful curation of clinical data, and an ethnically homogeneous set of patients and controls representing the largest sample set from the region of Central and Eastern Europe. Despite that, the number of individuals still did not allow the precise OC risk calculations in rarely mutated genes. Although all OC cases in the Czech Republic are eligible for genetic testing, OC patients with positive family cancer history and earlier-onset individuals were enriched in our study, especially in a small subgroup enrolled before 2015 (in the Center A only).

Whether the high prevalence of clinically important germline mutations in OC patients justifies population-wide screening is a vivid matter of debate \[[@B44-cancers-12-00956],[@B45-cancers-12-00956],[@B46-cancers-12-00956],[@B47-cancers-12-00956],[@B48-cancers-12-00956]\]. We emphasize that we found *BRCA1/2* mutations in 14.5% of OC patients with no family cancer history who would currently not be revealed presymptomatically without population screening. We assume that careful application of germline testing in all OC patients and their relatives would reduce OC burden in our population. Moreover, the mutations in *BRCA1/2* \[[@B49-cancers-12-00956],[@B50-cancers-12-00956]\] and other OC predisposition genes \[[@B51-cancers-12-00956],[@B52-cancers-12-00956]\] represent valuable predictive biomarkers improving OC chemotherapy.

4. Materials and Methods {#sec4-cancers-12-00956}
========================

Analyzed patients (*N* = 1333) were enrolled in 2010--2018 and included all OC cases regardless of familial cancer history or OC histology subtypes. As knowledge about germline mutations' frequency in women diagnosed with BTO is limited, we included these histological subtypes to our study. Clinicopathological data were obtained during genetic counselling or retrieved from the patients' records. OC patients with a positive cancer family history were stratified into (i) hereditary ovarian cancer (HOC) families with OC and other nonbreast cancer (BC) in the family history; (ii) hereditary breast and/or ovarian cancer (HBOC) families with BC and OC or other cancer in the family history, and (iii) multiple cancer families with non-OC and non-BC in the family history. Index patients were tested in seven centers: (A) First Faculty of Medicine, Charles University, Prague (*N* = 637); (B) Masaryk Memorial Cancer Institute, Brno (*N* = 357); (C) Gennet, Prague (*N* = 273); (D) AGEL Laboratories, Novy Jicin (*N* = 34); (E) GHC Genetics (*N* = 12); (F) Pronatal (*N* = 11), and (G) University Hospital Olomouc (*N* = 9).

Population-matched controls (PMC; *N* = 2278) included 616 noncancer controls collected in centers A (*N* = 344), B (*N* = 150), and D (*N* = 122), and 1662 unselected controls provided by the National Center for Medical Genomics (<http://ncmg.cz>). The noncancer controls were volunteers (78 males and 538 females) aged ≥ 60 years without a personal or family cancer history (in first-degree relatives). The unselected controls (1170 males and 492 females; median age 57 years, range 18--88 years) were unrelated individuals analyzed by whole-exome sequencing (WES) for various noncancer conditions.

All patients and controls were Caucasians of a Czech origin. Written informed consent was obtained from all patients and controls. The study was approved by the Ethics Committee of the General University Hospital in Prague; ethics approval number was 92/14. The study was performed in accordance with the Declaration of Helsinki.

4.1. Next-Generation Sequencing {#sec4dot1-cancers-12-00956}
-------------------------------

Germline blood-derived DNA was analyzed by the CZECANCA (CZEch CAncer paNel for Clinical Application; custom-made SeqCap EZ choice panel; Roche) panel NGS targeting 219 genes on MiSeq (Illumina), as described in details previously \[[@B19-cancers-12-00956]\]. Sequencing reads were aligned by Novoalign v2.08.03 to the human reference genome (hg19). Variants were identified using GATK and Pindel, CNVs using CNV score \[[@B19-cancers-12-00956]\]. The entire diagnostic pipeline was successfully tested using European Molecular Genetics Quality Network schemes (EMQN) and validated as we have described recently \[[@B19-cancers-12-00956]\].

4.2. Variant Classification {#sec4dot2-cancers-12-00956}
---------------------------

We first analyzed 18 genes considered clinically relevant to the HBOC syndrome (MIM \#604370) by NCCN, namely, *ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MLH1, MSH2, MSH6, NBN, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11,* and *TP53.* Germline variants (with frequency ≤ 0.01 and ≤0.05 in 1000 Genomes project and noncancer PMC, respectively) were classified into three groups: i) pathogenic/likely pathogenic, ii) variants of unknown significance (VUS), and iii) likely benign/benign, based on recommendations from the ENIGMA consortium (<https://enigmaconsortium.org>). All nonsense/frameshift/splicing (± 1--2 bp) mutations/CNVs were considered pathogenic/likely pathogenic unless classified as other in the ClinVar database; whole gene duplications were considered VUS. The other types of mutations were considered pathogenic/likely pathogenic only if classified as such in ClinVar by at least two submitters. TP53 variants were classified using the IARC TP53 database (<http://p53.iarc.fr/>), *CHEK2* VUS using a recently published functional assay \[[@B27-cancers-12-00956]\].

Subsequently, we analyzed variants in another 201 genes targeted by the CZECANCA panel. Nonsense/frameshift/splicing (± 1--2 bp) mutations/CNVs (except whole gene duplications) with frequency ≤0.01 and ≤0.05 in 1000 Genomes project and in noncancer PMC, respectively, were considered pathogenic.

All pathogenic/likely pathogenic mutations in patients and noncancer PMC were confirmed by Sanger sequencing and CNVs by MLPA (if available) or by qPCR (protocol available on request), and they were submitted to ClinVar under the submission ID SUB5822876.

4.3. Statistical Analysis {#sec4dot3-cancers-12-00956}
-------------------------

The odds ratio (OR) for particular gene was calculated using Fisher's exact test, and p values \<0.05 were considered significant. The multiple mutation carriers were excluded from the OR calculations. For the identification of other OC candidate genes, the Bonferroni correction was employed. The associations between mutation status and clinicopathological characteristics were estimated using Fisher's exact test, and p values \<0.05 were considered significant.

5. Conclusions {#sec5-cancers-12-00956}
==============

Our study demonstrated that nearly one in three OC patients carries a pathogenic mutation in genes significantly associated with OC. The mutation frequency exceeded 10% in all clinicopathological subgroups, regardless of the age at diagnosis, clinical or histopathological characteristics, with an exception of women diagnosed with OC before the age of 30 or with rare histological OC subtypes. Importantly, we found that the high mutation prevalence included borderline tumors justifying genetic testing of all OC patients, including women diagnosed with borderline tumors. Surprisingly, *BRCA1/2* mutations were not associated with sporadic OC in very young women (≤30 years). Besides the established OC predisposition genes, *NBN* and *BARD1* were significantly associated with a moderate OC risk; however, further studies will be required to specify the associated OC risk and to identify the value of the detected genetic mutations in terms of disease prognosis and therapy prediction. Hence, analyses of rarely mutated BC/OC predisposition genes that failed to increase OC risk in our study are further warranted to evaluate their association with OC in future larger dataset and/or in frame of international consortia. These should include also other candidate alterations with predictive and/or prognostic potential.

We thank our patients for contribution in this study. We thank our clinical colleagues for their valuable comments to the manuscript and Jan Flemr for language editing.

The following are available online at <https://www.mdpi.com/2072-6694/12/4/956/s1>, Table S1: the clinicopathological characteristics of 1333 ovarian cancer patients, Table S2: mutation frequencies in ovarian cancer cases and population-matched controls, Table S3: clinical and pathological characteristics in multiple mutation carriers, Table S4: clinicopathological characteristics of mutation carriers in HBOC genes listed in NCCN guidelines (mutation carriers in a group of 1320 ovarian cancer patients (after exclusion of 13 multiple mutation carriers shown in Table S3) (10 genes significantly associated with OC risk in our study are highlighted), Table S5: mutations in 201 additional analyzed genes with associated OC risk (significantly associated genes (*p* \< 0.05) are highlighted), Table S6: characteristics of 15 *PPM1D* mutation carriers, and Table S7: clinicopathological characteristics of mutation carriers in *NAT1*, *PPM1D*, and *SHPRH* significantly associated with OC risk.
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cancers-12-00956-t001_Table 1

###### 

Mutation frequencies in 1320 ovarian cancer cases and in 2278 population-matched controls (PMC).

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                                                          1320 OC Patients ^(a)^\   2278 PMC\         OR (95% CI); p ^(a)^
                                                                N Mutations (%)           N mutations (%)   
  ------------------------------------------------------------- ------------------------- ----------------- ----------------------------------------
  Increased OC risk ^(b)^                                                                                   

   ***BRCA1 ^(^*^c)^**                                          **229 (17.35)**           **5 (0.22)**      **95.2 (40.1--295.2); 1.83 × 10^−97^**

   ***BRCA2 ^(^*^c)^**                                          **94 (7.12)**             **7 (0.31)**      **24.9 (11.6--63.6); 1.16 × 10^−33^**

   ***RAD51D***                                                 **13 (0.98)**             **2 (0.09)**      **11.3 (2.6--103.4); 9.66 × 10^−5^**

   ***RAD51C***                                                 **13 (0.98)**             **4 (0.18)**      **5.7 (1.7--23.8); 0.001**

   ***BRIP1 ^(c)^***                                            **10 (0.76)**             **5 (0.22)**      **3.5 (1.1--13); 0.03**

   ***MLH1 ^(c)^***                                             **4 (0.3)**               **1 (0.04)**      6.9 (0.7--340.4); 0.06 ^(d)^

   ***MSH2***                                                   **3 (0.23)**              **0**             **0.049 ^(d)^**

   ***MSH6***                                                   **3 (0.23)**              **0**             **0.049 ^(d)^**

   *STK11*                                                      2 (0.15)                  0                 0.13

  Potentially increase or insufficient evidence OC risk ^(b)^                                               

   ***NBN ^(c)^***                                              **14 (1.06)**             **7 (0.31)**      **3.5 (1.3--10.2); 0.006**

   *PALB2*                                                      8 (0.61)                  9 (0.40)          1.5 (0.5--4.5); 0.45

   *ATM ^(c)^*                                                  6 (0.45)                  8 (0.35)          1.3 (0.4--4.3); 0.78

   ***BARD1 ^(c)^***                                            **3 (0.23)**              **0**             **0.049**

  No increased risk of OC ^(b)^                                                                             

   *CHEK2 ^(c)^*                                                11 (0.83)                 8 (0.35)          2.4 (0.9--6.8); 0.06

   *TP53* ^(c)^                                                 1 (0.08)                  2 (0.09)          0.9 (0--16.6); 1

   *CDH1* ^(c)^                                                 0                         0                 \-

   *PTEN* ^(c)^                                                 0                         0                 \-

   *NF1*                                                        0                         0                 \-
  --------------------------------------------------------------------------------------------------------------------------------------------------

^(a)^ Prevalence of mutations in all 1333 patients (including 13 multiple mutation carriers) is provided in [Table S2](#app1-cancers-12-00956){ref-type="app"}. ^(b)^ Gene classification according to the NCCN guidelines version 2020.1. ^(c)^ Excluding 13 multiple mutation carriers described in [Figure 1](#cancers-12-00956-f001){ref-type="fig"} and [Table S3](#app1-cancers-12-00956){ref-type="app"}. ^(d)^ When analyzed Lynch syndrome genes collectively: OR = 22.63 (95% CI 3.4--958.5); *p* = 1.95 × 10^−05^.

cancers-12-00956-t002_Table 2

###### 

Additional 201 analyzed genes significantly associated with OC risk in the group of all OC patients and in a subgroup of 934 patients without mutations in 10 established OC predisposition genes.

  Gene                                                                                          Patients N Mutations (%)   2278 PMC N Mutations (%)   OR (95% CI); p (Bonferroni Corrected *p*)
  --------------------------------------------------------------------------------------------- -------------------------- -------------------------- --------------------------------------------
  All 1333 OC patients                                                                                                                                
   ***PPM1D***                                                                                  16 (1.20)                  2 (0.09)                   13.82 (3.24--124.22); 7.4 × 10^−6^ (0.001)
   ***NAT1***                                                                                   13 (0.98)                  5 (0.22)                   4.48 (1.49--16.07); 0.003 (n.s.)
   ***SHPRH***                                                                                  5 (0.38)                   1 (0.04)                   8.57 (0.96--404.83); 0.028 (n.s.)
  934 OC patients without mutations in 10 genes significantly associated with OC in our study                                                         
   ***PPM1D***                                                                                  12 (1.28)                  2 (0.09)                   14.80 (3.28--136.67); 1.7 × 10^−5^ (0.003)
   ***NAT1***                                                                                   8 (0.86)                   5 (0.22)                   3.96 (1.13--15.30); 0.026 (n.s.)
   ***MMP8***                                                                                   6 (0.64)                   4 (0.18)                   3.67 (0.87--17.74); 0.041 (n.s.)
   ***FANCG***                                                                                  5 (0.53)                   2 (0.09)                   6.12 (1.00--64.45); 0.025 (n.s.)

n.s., nonsignificant.
